Roivant Sciences reported second quarter 2026 revenue of US$35.12 million and a net loss of US$191.62 million, and confirmed completion of a US$393.94 million share repurchase program that retired 13,632,008 shares. The first commercial weeks of LISRIA generated US$31 million in net revenue and were accompanied by encouraging data readouts across IMVT-1402, Mosliciguat and brepocitinib, highlighting how Roivant Sciences is pairing clinical progress with early product uptake. We will now...
Roivant Sciences has seen its stock deliver significant gains in recent years, which naturally raises the question of whether the current share price still lines up with the value on its balance sheet. With the stock now reflecting years of optimism, investors are asking how that compares with what its book value can support. Over the past 5 years, Roivant Sciences has returned about 383.9%. This puts a lot of weight on whether the underlying net assets justify where the share price has...
Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.
Here are some of the companies making headlines in midday trading.
Citi adds Roivant to its 90-day catalyst watch ahead of CLARITY phase 3 brepocitinib data. Read more here.
Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.
Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 30.08% on an annualized basis producing an average annual return of 41.86%. Currently, Roivant Sciences has a market capitalization of
On Thursday, Roivant Sciences (NASDAQ:ROIV) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 27.07% on an annualized basis producing an average annual return of 39.09%. Currently, Roivant Sciences has a market capitalization of
Roivant Sciences (NASDAQ:ROIV) CEO Matthew Gline outlined the company’s priorities for the next 12 months, including the launch of LISRAYA, upcoming clinical data for brepocitinib and Immunovant’s IMVT-1402, and expansion of its pulmonary hypertension program. Gline said Roivant recently received a
Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
Roivant Sciences Ltd. (NASDAQ:ROIV) shares jumped about 17% after the company reported positive mid-stage results for mosliciguat, its experimental treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The readout gives Roivant (NASDAQ:ROIV) another late-stage pipeline opportunity shortly after the company won U.S. approval for Lisraya, its treatment for adults with dermatomyositis. READ ALSO: […]
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
This study enrolled 57 adult patients with CLE, who were assigned to receive either IMVT-1402 or a placebo.
Immunovant halts IMVT-1402 CLE trial after missing primary endpoints, driving IMVT and Roivant shares down in premarket trading.
Roivant Sciences (NASDAQ:ROIV) said its majority-owned subsidiary Immunovant will discontinue development of IMVT-1402, also known as imeroprubart, in cutaneous lupus erythematosus after a proof-of-concept study failed to meet its primary endpoint. The randomised, double-blind, placebo-controlled trial enrolled 57 adults with cutaneous lupus erythematosus.
Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant’s internal bar to continue development of IMVT-140
Roivant Sciences Ltd. (NASDAQ:ROIV) may be entering the most important phase of its business, as its pipeline begins to move from clinical development to commercialization. Stifel initiated coverage of Roivant with a Buy rating and a $51 price target on September 16. The target implied a roughly 29% upside from the stock price at that […]
Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.